Compare DY & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DY | GKOS |
|---|---|---|
| Founded | 1969 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Water Sewer Pipeline Comm & Power Line Construction | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.3B | 10.6B |
| IPO Year | 1995 | 2015 |
| Metric | DY | GKOS |
|---|---|---|
| Price | $273.80 | $154.92 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 12 |
| Target Price | ★ $425.30 | $126.92 |
| AVG Volume (30 Days) | 617.4K | ★ 636.1K |
| Earning Date | 05-20-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.71 | N/A |
| EPS | ★ 6.81 | N/A |
| Revenue | N/A | ★ $507,442,000.00 |
| Revenue This Year | $30.96 | $23.32 |
| Revenue Next Year | $9.49 | $27.43 |
| P/E Ratio | $39.96 | ★ N/A |
| Revenue Growth | N/A | ★ 32.33 |
| 52 Week Low | $271.87 | $73.16 |
| 52 Week High | $566.47 | $191.62 |
| Indicator | DY | GKOS |
|---|---|---|
| Relative Strength Index (RSI) | 30.72 | 33.05 |
| Support Level | N/A | $145.78 |
| Resistance Level | $309.48 | $161.53 |
| Average True Range (ATR) | 10.92 | 7.06 |
| MACD | 2.31 | -2.33 |
| Stochastic Oscillator | 8.10 | 11.50 |
Dycom Industries Inc is a provider of specialty contracting services to the telecommunications infrastructure and utility industries throughout the United States. The company has two reporting segments: Communications and Building Systems. The Communications segment provides specialty contracting services, including program management, planning; engineering and design; aerial, underground, and wireless construction; maintenance; and fulfillment services for telecommunications and digital infrastructure providers. The Building Systems segment specializes in providing comprehensive building infrastructure solutions, including electrical, energy management, security, and fire safety systems for data centers and other critical facilities. The firm generates key revenue from Communications.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.